/
Oncology
Breast Cancer
2.2K
Pipeline Programs↗
1.3K
Active Trials↗
423
Companies Involved↗
Breast Cancer is a highly competitive landscape with 2207 programs across 423 companies. The most active players are AstraZeneca, Roche, Novartis. 112 therapies are approved with 407 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical190
Phase 1363
Phase 21135
Phase 3407
Analysis
Modality Breakdown
88%
Small molecule
2,345 of 2,668 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 2,668 classified programs, each share of the total. Modality classified for 98% of 2,894 pipeline programs.
Analysis
Trial Status
5,223
clinical trials
Completed2,397 · 46%
Unknown status679 · 13%
Recruiting644 · 12%
Terminated617 · 12%
Active, not recruiting379 · 7%
Not yet recruiting282 · 5%
Other225 · 4%
Clinical Trials
Trial Activity
5223 trials
Page 1 of 349
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)